KAT2A and colorectal carcinoma: First, we utilized three patient-derived 3D spheroid models (CRC1, CRC2, CRC3) and treated them with increasing concentrations of the two chemical HAT/KAT2A inhibitors, MB-3 [36] and CPTH2 [37], to determine the half-maximal inhibitory concentrations (IC50) for each CRC model.